Theralase Technologies Inc. filed its Annual on Apr 26, 2023 for the period ending Dec 31, 2022. In this report its auditor, Richter LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.165 CAD | +3.12% | +3.12% | -5.71% |
Apr. 24 | Theralase Technologies Inc. announced that it has received CAD 0.7502 million in funding | CI |
Apr. 05 | Theralase Technologies Inc. Receives Canadian Cancer Vaccine Patent | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-5.71% | 28.95M | |
+6.46% | 899M | |
-26.24% | 234M | |
-38.71% | 71.85M | |
+23.51% | 68.59M |
- Stock Market
- Equities
- TLT Stock
- News Theralase Technologies Inc.
- Theralase Technologies Inc. Auditor Raises 'Going Concern' Doubt